At the news
? BULLISHIMPACT 7/10 8-K filed May 12, 2026 at 17:24 ET
Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer for VEPPANUTM (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. Rigel will pay $70M upfront, $15M on transition completion, up to $320M in milestones, plus tiered royalties, and reimburse up to $40M in development costs. The deal provides Rigel with a commercial-stage asset, representing a significant pipeline and revenue opportunity.
- Rigel obtains exclusive worldwide license for VEPPANU (vepdegestrant), an approved ER+/HER2- breast cancer drug.
- Upfront payment of $70 million, plus $15 million upon successful transition completion.
- Up to $320 million in regulatory and sales milestone payments ($60M regulatory, $260M sales).
- Tiered royalties on net sales from mid-teens to mid-twenties percentages.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access